PZ Cussons plc (LSE:PZC) shares advanced 9.17% to GBX 87.66 during the morning session on 11 February 2026 after reporting its results for the six months ended 29 November 2025 (H1 FY26), alongside an upgrade to full-year operating profit expectations.
Renalytix PLC (LSE:RENX) saw its share price fall sharply in early trading on 11 February, down 24.11% to4.25pat10:35 am, as investors reacted to the company’s trading update for the six months ended 31 December 2025 (H1 FY26). The decline comes amid indications of slower-than-anticipatedrevenuegrowth …
Arecor Therapeutics plc (LSE:AREC), the biopharmaceutical company focused on diabetes and cardiometabolic therapies, released an unaudited business update for the 12 months ending 31 December 2025. The report outlines developments across its core product areas, financial performance, and strategic collaborations, while the audited results …
Verici Dx PLC (AIM:VRCI) shares traded 3.10% lower to GBX 0.70 during the morning session on 5 February 2026, extending yearly decline to 81.27%, Today’s decline came despite the release of a trading update outlining revenue growth and commercial progress for the year ended …
GSK plc (LSE:GSK) shares moved higher on Wednesday, trading at GBX 2,019.03, up 3.78% on the day. The stock has gained 46.31% over the past year and 10.91% over the last month.
Shares in hVIVO PLC (LON:HVO) have fallen more than 69% over the past year, bringing renewed focus on analyst views and the company’s latest trading update. Despite the decline, broker opinions remain divided, with hold ratings from Stifel Europe and Panmure Liberum alongside a …
AstraZeneca plc (LSE:AZN) has begun trading its ordinary shares on theNew York Stock Exchange(NYSE) from 2 February 2026, marking a change in the company’s global listing arrangements. With this move, AstraZeneca’s ordinary shares are now traded across the NYSE, theLondon Stock Exchange(LSE) and Nasdaq …
AstraZeneca PLC (LSE:AZN) has entered into a strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of next-generation therapies targeting obesity and type 2 diabetes (T2D). The agreement covers eight development programmes, including one clinical-ready asset and multiple preclinical candidates.
Kooth PLC (LSE:KOO), a provider of digital mental health services, has announced a trading update for the financial year ended 31 December 2025. The update details revenue performance, contract wins in the US, and operational progress in California and the UK, while outlining expectations …
AstraZeneca plc (LSE:AZN) remains firmly in the spotlight after receiving a fresh endorsement from Rothschild & Co Redburn, even as its share price edges closer to broader market expectations. The stock closed at GBX 14,020.00 on 16 January, marginally lower on the day, but …